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Aims The PARADIGM-HF and PARAGON-HF trials tested sacubitril/valsartan against active controls given renin–angio-
tensin system inhibitors (RASi) are ethically mandated in heart failure (HF) with reduced ejection fraction and are
used in the vast majority of patients with HF with preserved ejection fraction. To estimate the effects of sacubitril/
valsartan had it been tested against a placebo control, we made indirect comparisons of the effects of sacubitril/val-
sartan with putative placebos in HF across the full range of left ventricular ejection fraction (LVEF).
...................................................................................................................................................................................................
Methods
and results
We analysed patient-level data from the PARADIGM-HF and PARAGON-HF trials (n= 13 194) and the CHARM-
Alternative and CHARM-Preserved trials (n= 5050, candesartan vs. placebo). The rate ratio (RR) of sacubitril/valsar-
tan vs. putative placebo was estimated by the product of the RR for sacubitril/valsartan vs. RASi and the RR for RASi
vs. placebo. Total HF hospitalizations and cardiovascular death were analysed using the negative binomial method.
Treatment effects were estimated using cubic spline methods by ejection fraction as a continuous measure. Across
the range of LVEF, sacubitril/valsartan was associated with a RR 0.54 [95% confidence interval (CI) 0.45–0.65] for the
recurrent primary endpoint compared with putative placebo (P< 0.001). Treatment benefits of sacubitril/valsartan vs.
putative placebo varied non-linearly with LVEF with attenuation of effects observed at LVEF above 60%. When analyz-
ing data from PARADIGM-HF and CHARM-Alternative, the estimated risk reduction of sacubitril/valsartan vs. putative
placebo was 48% (95% CI 35–58%); P< 0.001. When analyzing data from PARAGON-HF and CHARM-Preserved
(with LVEF >_ 45%), the estimated risk reduction of sacubitril/valsartan vs. putative placebo was 29% (95% CI 7–46%);
P= 0.013. Across the full range of LVEF, consistent effects were observed for time-to-first endpoints: first primary
endpoint (RR 0.72, 95% CI 0.64–0.82), first HF hospitalization (RR 0.67, 95% CI 0.58–0.78), cardiovascular death (RR
0.76, 95% CI 0.64–0.89), and all-cause death (RR 0.83, 95% CI 0.71–0.96); all P< 0.02.
...................................................................................................................................................................................................
Conclusion This putative placebo analysis reinforces the treatment benefits of sacubitril/valsartan on risk of adverse cardiovas-
cular events across the full range of LVEF, with most pronounced effects observed at a LVEF up to 60%.
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Introduction
The angiotensin receptor neprilysin inhibitor (ARNI), sacubitril/val-
sartan, was tested against active comparators in paired, similarly
designed trials of heart failure (HF) that covered the spectrum of left
ventricular ejection fraction (LVEF).1 Trials were designed to test the
value of neprilysin inhibition, added to standard background therapy,
inclusive of renin–angiotensin system inhibitors (RASi). The
PARADIGM-HF (Prospective comparison of ARNI with ACEI to
Determine Impact on Global Mortality and morbidity in Heart
Failure) trial2 compared sacubitril/valsartan against enalapril, as
angiotensin-converting enzyme inhibitors (ACEi) are ethically man-
dated background therapy, represent the regulatory gold standard,
and are supported by Class I, level of evidence A recommendations
by international guidelines in HF with reduced ejection fraction
(HFrEF).3,4 The PARAGON-HF (Prospective Comparison of ARNI
with ARB Global Outcomes in HF With Preserved Ejection Fraction)
trial5 compared sacubitril/valsartan against valsartan, as RASi are used
in the vast majority of patients with HF with preserved ejection frac-
tion (HFpEF) to achieve blood pressure control and to treat comor-
bidities (such as diabetes mellitus, chronic kidney disease, and
coronary artery disease) to goals recommended by clinical practice
guidelines.3,4 While these trials inform the incremental efficacy and
safety of ARNI compared with RASi, regulators and clinicians may be
interested in understanding the combined effects of ARNI when
compared with placebo. We employed established statistical
approaches to estimate treatment effects of ARNI against a putative
placebo comparator, leveraging data from two large clinical trial pro-
grammes evaluating sacubitril/valsartan and the angiotensin receptor
blocker (ARB), candesartan, across the full range of LVEF.
Methods
Putative placebo analysis
To estimate the effects of RASi against placebo, we analysed patient-level
data from PARADIGM-HF/PARAGON-HF trials and the CHARM
(Candesartan in Heart failure—Assessment of Reduction in Mortality and
morbidity)-Alternative/CHARM-Preserved trials. We employed an
established method of indirect comparisons6–8 that has been previously
applied to estimate the effects of ARNI vs. putative placebo in HFrEF.9
Treatment estimates of sacubitril/valsartan vs. putative placebo were esti-
mated as the product of sacubitril/valsartan vs. RASi (derived from the
PARADIGM-HF and PARAGON-HF trials) and RASi vs. placebo (derived
from the CHARM-Alternative and CHARM-Preserved trials). The 95%
confidence interval (CI) was estimated based on the square root of the
sum of both squared standard errors of the logarithmic rate ratios (RRs).
This approach relies on the assumption that the relative effects of sacubi-
tril/valsartan vs. enalapril or valsartan would be comparable to that when
compared with candesartan.
PARADIGM-HF and PARAGON-HF
PARADIGM-HF2 and PARAGON-HF5 were global, randomized, active-
controlled clinical trials comparing sacubitril/valsartan vs. RASi in HF.
Both trials enrolled symptomatic patients with HF and New York Heart
Association (NYHA) class II-IV; PARADIGM-HF and PARAGON-HF
patients had to be on RASi and diuretic therapy, respectively, during the
month prior to enrolment. PARADIGM-HF patients were also required
to be on a b-blocker (unless contraindicated or not tolerated) and a
mineralocorticoid receptor antagonist (if indicated). Patients were
required to have elevated natriuretic peptides (with variable thresholds
based on recent HF hospitalization and history of atrial fibrillation/flutter).
PARAGON-HF additionally required patients to have evidence of struc-
tural heart disease (left atrial enlargement or left ventricular hyper-
trophy). PARADIGM-HF enrolled patients with an LVEF of 40% or less
and PARAGON-HF included patients with LVEF of 45% or greater.
Patients who tolerated run-in periods (sequential titration phases of RASi
followed by ARNI) were subsequently randomized to sacubitril/valsartan
vs. enalapril (in PARADIGM-HF) or valsartan (in PARAGON-HF). The
primary endpoint of PARADIGM-HF was time to first cardiovascular
death or HF hospitalization and that of PARAGON-HF was total (first
and recurrent) HF hospitalizations and cardiovascular death. Endpoints
were centrally adjudicated by an independent clinical endpoints commit-
tee. PARADIGM-HF enrolled patients from 2009 to 2012 with median
follow-up of 27 months. PARAGON-HF enrolled patients from 2014 to
2016 with median follow-up of 35 months. Pooling of individual patient-
level data from both trials was prespecified to interpolate between LVEF
40–45% (a range not covered by eligibility criteria in either trial).
CHARM programme
This analysis focused on patients enrolled in CHARM-Alternative and
CHARM-Preserved. We excluded CHARM-Added as patients enrolled
in this trial were already treated with ACEi, and thus do not reflect an un-
treated patient population (free from RASi). CHARM-Alternative10
enrolled symptomatic HF patients with NYHA Class II–IV and LVEF
<_40% who were intolerant to an ACEi. CHARM-Preserved11 enrolled
patients with HF and NYHA Class II–IV symptoms and LVEF >40%.
Initially, in CHARM-Preserved, ACEi were not allowed as concomitant
treatment, but after publication of the Heart Outcomes Prevention
Evaluation trial results, their use was optional in appropriate patients. The
CHARM programme enrolled patients between 1999 and 2001 and me-
dian follow-up was 34 months (for CHARM-Alternative) and 37 months
(for CHARM-Preserved). The primary endpoint was time-to-first cardio-
vascular death or hospitalization for HF. Endpoints were centrally adjudi-
cated by a clinical endpoints committee.
Left ventricular ejection fractions were based site-assessed measures
at entry in all trials. The primary endpoint for this analysis was total HF
hospitalizations and cardiovascular death. We analysed additional end-
points using time-to-first event analyses: composite of cardiovascular
death or first HF hospitalization, each of its components, and all-cause
mortality. Relative treatment effects were modelled using Poisson regres-
sion models (for time-to-first event analyses) and negative binomial mod-
els (for recurrent event analyses). In addition, to remain consistent with
the protocol-specified approach to handling recurrent events in
PARAGON-HF,2 we separately analyzed the primary endpoint using a
semiparametric proportional rates method developed by Lin, Wei, Yang,
and Ying. Treatment effects (sacubitril/valsartan vs. putative placebo)
were estimated using restricted cubic spline methods by LVEF as a con-
tinuous measure. We further analysed treatment effects separately in
HFrEF (with data from PARADIGM-HF and CHARM-Alternative) and
HFpEF (with data from PARAGON-HF and CHARM-Preserved). For
this indirect comparison, to keep criteria consistent between trials, we
restricted CHARM-Preserved to LVEF >_45% (excluding 450 patients).
We additionally carried out a sensitivity analysis evaluating treatment
effects relative to an alternative LVEF cut-point (above and below 60%).
All statistical analyses were performed using STATA 14.1 (College
Station, TX, USA).
2 M. Vaduganathan et al.
D
ow
nloaded from
 https://academ
ic.oup.com
/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehaa184/5813082 by guest on 08 April 2020
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..Results
We analysed individual patient-level data from the PARADIGM-HF
and PARAGON-HF trials (n= 13 195, sacubitril/valsartan vs. RASi)
and the CHARM-Alternative and CHARM-Preserved trials
(n= 5051, candesartan vs. placebo); Table 1. While patients enrolled
in CHARM-Alternative were on average older than in PARADIGM-
HF, patients enrolled in CHARM-Preserved were younger than in
PARAGON-HF. Patients in the more contemporary PARADIGM-
HF/PARAGON-HF trials had lower systolic blood pressures and
rates of prior myocardial infarction, higher rates of atrial fibrillation,
and diabetes mellitus and were more frequently NYHA functional
class II compared with patients enrolled in CHARM. Mean LVEF was
39.7± 15.1% in PARADIGM-HF/PARAGON-HF and 44.3 ± 14.7% in
the CHARM programme; LVEF was broadly represented in both clin-
ical trial programmes (Supplementary material online, Figure S1).
Rates of use of ACEi/ARB, b-blockers, and mineralocorticoid recep-
tor antagonists were markedly higher in both PARADIGM-HF and
PARAGON-HF compared with the corresponding CHARM trials.
During follow-up, incidence rates of recurrent primary endpoints
were higher in CHARM-Alternative [1524 events; 29.1 (26.6–31.7)
per 100 patient-years] compared with in PARADIGM-HF [3179
events; 17.1 (16.3–18.1) per 100 patient-years]. Risks of recurrent
primary endpoints were more comparable between CHARM-
Preserved [1308 events; 14.8 (13.5–16.2) per 100 patient-years] and
PARAGON-HF [1903 events; 13.7 (12.8–14.8) per 100 patient-
years].
In the overall trial programmes, sacubitril/valsartan reduced the re-
current primary endpoint by 21% (95% CI 13–29%) compared with
RASi, while candesartan led to a 31% (95% CI 19–41%) event reduc-
tion compared with placebo (both P< 0.001). Applying indirect com-
parisons, sacubitril/valsartan reduced the recurrent primary endpoint
by 46% (95% CI 35–55%) compared with putative placebo
(P< 0.001). In examining PARADIGM-HF as the active comparator
trial and CHARM-Alternative as the reference trial, the estimated
risk reduction of sacubitril/valsartan vs. putative placebo was 48%
(95% CI 35–58%); P< 0.001. In examining PARAGON-HF as the ac-
tive comparator trial and CHARM-Preserved (restricted to LVEF >_
45%, excluding 450 patients to keep criteria consistent between tri-
als) as the reference trial, the estimated risk reduction of sacubitril/
valsartan vs. putative placebo was 29% (95% CI 7–46%); P= 0.013
(Figure 1). Qualitatively similar results were obtained when analyzing
....................................................................................................................................................................................................................
Table 1 Selected trial design elements and baseline characteristics
CHARM-Alternative
(n5 2028)
PARADIGM-HF
(n5 8399)
CHARM-Preserved
(n5 3023)
PARAGON-HF
(n5 4796)
Comparison Candesartan
vs. placebo
Sacubitril/valsartan
vs. enalapril
Candesartan
vs. placebo
Sacubitril/valsartan
vs. valsartan
Enrolment window 1999–2001 2009–12 1999–2000 2014–16
Median follow-up (months) 34 27 37 35
Age (years) 66.1 ± 10.8 63.8 ± 11.4 66.7 ± 11.1 72.7 ± 8.4
Women 646 (31.9%) 1832 (21.8%) 1212 (40.1%) 2479 (51.7%)
Body mass index (kg/m2), mean ± SD 27.4 ± 4.9 28.2 ± 5.5 29.2 ± 5.8 30.2 ± 5.0
Systolic blood pressure (mmHg), mean ± SD 130.1 ± 18.7 121.4 ± 15.3 136.2 ± 18.4 130.6 ± 15.5
Heart rate (b.p.m.), mean ± SD 74.4 ± 13.6 72.4 ± 12.0 71.3 ± 12.5 70.4 ± 12.3
Left ventricular ejection fraction (%), mean ± SD 29.9 ± 7.4 29.5 ± 6.2 54.0 ± 9.4 57.5 ± 7.9
New York Heart Association class
1 0 (0%) 389 (4.6 %) 0 (0%) 137 (2.9 %)
2 966 (47.6%) 5919 (70.6%) 1836 (60.7%) 3706 (77.3%)
3 989 (48.8%) 2018 (24.1%) 1140 (37.7%) 932 (19.4%)
4 73 (3.6 %) 60 (0.7 %) 47 (1.6 %) 19 (0.4 %)
Atrial fibrillation 515 (25.4%) 3091 (36.8%) 881 (29.1%) 1552 (32.5%)
Diabetes mellitus 548 (27.0%) 2907 (34.6%) 857 (28.3%) 2062 (43.0%)
Prior stroke 175 (8.6 %) 725 (8.6 %) 268 (8.9 %) 508 (10.6%)
Prior MI 1247 (61.5%) 3634 (43.3%) 1340 (44.3%) 1083 (22.6%)
Prior hospitalization for HF 1385 (68.3%) 5274 (62.8%) 2076 (68.7%) 2306 (48.1%)
Diuretics 1733 (85.5%) 6738 (80.2%) 2259 (74.7%) 4585 (95.6%)
MRAa 103 (5.1 %) 4671 (55.6%) 144 (4.8 %) 1239 (25.8%)
ACEi/ARBb 3 (0.1 %) 8379 (99.8%) 576 (19.1%) 4139 (86.3%)
b-blocker 1106 (54.5%) 7811 (93.0%) 1684 (55.7%) 3821 (79.7%)
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; HF, heart failure; MI, myocardial infarction; MRA, mineralocorticoid receptor antagonist; SD,
standard deviation.
aIn CHARM trials, spironolactone was the MRA captured in this category.
bIn CHARM trials, only prior ACEi use was permitted.
Sacubitril/valsartan vs. putative placebo 3
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Figure 1 Schematic of the indirect comparisons used to estimate the effects of sacubitril/valsartan vs. putative placebo. The CHARM programme
compared candesartan vs. placebo. PARADIGM-HF and PARAGON-HF compared sacubitril/valsartan vs. a renin–angiotensin system inhibitor. Solid
lines represent direct comparisons performed in clinical trials, whereas the dashed lines represent indirect comparisons estimating the effects of sacu-
bitril/valsartan vs. putative placebo. The endpoint was the recurrent primary endpoint of total heart failure hospitalizations and cardiovascular death,
analysed using negative binomial methods. *Restricted to CHARM-Preserved patients with ejection fraction >_45%; excluding 450 patients with left
ventricular ejection fraction <45% to keep consistent with eligibility criteria in PARAGON-HF. ACEi, angiotensin-converting enzyme inhibitor; ARB,
angiotensin receptor blocker; CI, confidence interval; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection
fraction; RR, rate ratio.
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Take home figure Estimated treatment effects of sacubitril/valsartan vs. putative placebo across the full range of left ventricular ejection frac-
tion. (A) Recurrent event analysis using a negative binomial model, for total heart failure hospitalizations and cardiovascular death. (B–D) Time-to-first
analyses using Poisson regression models for first heart failure hospitalization or cardiovascular death, cardiovascular death, and all-cause mortality,
respectively. Treatment effects were estimated using cubic spline methods by LV ejection fraction as a continuous measure. Density of patients at
given left ventricular ejection fraction ranges is displayed in the table. CI, confidence interval; CV, cardiovascular; LV, left ventricular; RR, rate ratio.
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..the recurrent primary endpoint with the semiparametric proportion-
al rates method instead of the negative binomial method
(Supplementary material online, Results).
In spline analyses (Take home figure), treatment benefits with respect
to the recurrent primary endpoint of sacubitril/valsartan vs. putative
placebo varied non-linearly with LVEF; Pinteraction = 0.03 for LVEF above
vs. below 50%. Sensitivity analysis selecting an alternative LVEF cut-
point demonstrated that the effect of sacubitril/valsartan vs. putative
placebo were robust at LVEF <_ 60% [RR 0.50 (0.41–0.61); P< 0.001]
but not in patients with LVEF >60% [RR 1.00 (0.59–1.69); P= 1.00]. In
the aggregate analysis across the full range of LVEF, consistent effects
were observed for time-to-first endpoints: first primary endpoint [RR
0.72 (0.64–0.82)], first HF hospitalization [RR 0.67 (0.58–0.78)], cardio-
vascular death [RR 0.76 (0.64–0.89)], and all-cause mortality [RR 0.83
(0.71–0.96)]; all P< 0.02; Figure 2. Treatment benefits of sacubitril/val-
sartan vs. putative placebo on first and recurrent primary endpoints
extended to a higher LVEF compared with its effects on cardiovascular
death and all-cause mortality (Take home figure).
Discussion
As supported by clinical practice guidelines,3,4 RASi are established in
the treatment of HFrEF. Given the high-risk nature of HF, withholding
standard of care therapy (e.g. RASi) in a placebo-controlled trial was
considered unethical in the evaluation of sacubitril/valsartan in HFrEF.
While guidelines support management of prevalent comorbidities of
HFpEF,3,4 there is currently no pharmacological standard of care for
this cohort of patients. Renin–angiotensin system inhibitors are wide-
ly used among patients with HFpEF, mostly in the treatment of hyper-
tension. Since the addition of sacubitril/valsartan to background ACEi
may increase risks of angioedema, a placebo-controlled trial could
not be practically carried out and an active control (valsartan) was in-
stead selected as the comparator in PARAGON-HF. As such, we
conducted a comprehensive putative placebo analysis to estimate the
treatment effects of sacubitril/valsartan if a placebo was selected
across key cardiovascular endpoints. We uniquely leveraged pooled,
patient-level data from the only clinical trials examining ARNI and
RASi across the full range of LVEF. These data reinforce the robust
clinical benefits of sacubitril/valsartan in HF. In the aggregate analysis
across the full range of LVEF, we estimate treatment effects of 46%
reductions in total HF hospitalizations and cardiovascular death.
However, we detected notable non-linearity in the treatment effects
with event reductions waning at higher LVEF, especially above 60%.
Event reductions for the recurrent primary endpoint were estimated
to be 48% (when assessing PARADIGM-HF and CHARM-
Alternative) and 29% (when assessing PARAGON-HF and CHARM-
Figure 2 Forest plot of indirect comparisons used to estimate the effects of sacubitril/valsartan vs. putative placebo across a broad range of end-
points. PARADIGM-HF and PARAGON-HF compared sacubitril/valsartan vs. a renin–angiotensin system inhibitor. The CHARM programme com-
pared candesartan vs. placebo. Black lines represent direct comparisons performed in clinical trials, whereas the red lines represent indirect
comparisons estimating the effects of sacubitril/valsartan vs. putative placebo. All endpoints were analysed using time-to-first event analyses. ACEi,
angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CI, confidence interval; CV, cardiovascular; HF, heart failure; RR, rate
ratio.
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Preserved). Across the spectrum of LVEF, consistent reductions
were observed for all cardiovascular events and mortality endpoints
analysed.
Ideally, active-controlled and reference trials are similarly designed
in the same era of background therapy with comparable reference
drugs and dosing. However, as CHARM is the only clinical trial pro-
gramme which evaluated a RASi in symptomatic HF across the full
range of LVEF with long-term outcomes, this was selected as the his-
torical reference comparator. While the SOLVD (Studies of Left
Ventricular Dysfunction) Treatment trial could have been used as a
comparator for PARADIGM-HF, patients were enrolled in this trial
from 1986 to 1989 and CHARM-Alternative reflects a more conser-
vative treatment effect estimate (as candesartan displayed relatively
less benefit than enalapril as compared with placebo).12 As such, the
RASi evaluated in the active-controlled trials (PARADIGM-HF and
PARAGON-HF) differed from that studied in the reference trials
(CHARM-Alternative and CHARM-Preserved). While irbesartan, an-
other ARB, has been studied in HFpEF,13 the agent has not been
studied in a comparable trial in HFrEF. However, it is reassuring that
valsartan 160 mg twice daily (as tested in PARAGON-HF) and cande-
sartan 32 mg once daily (as tested in CHARM) both have similarly po-
tent biological activity in blood pressure lowering14 and both
represent target doses in contemporary guidelines.15 It is further
reassuring that the primary endpoints (either first or total HF hospi-
talization and/or cardiovascular death) were common across trials,
and events were adjudicated under similar rigorous procedures by in-
dependent clinical endpoints committees.
These analyses further inform decision-making surrounding use of
sacubitril/valsartan in HF. Estimation of the placebo-controlled re-
sponse of a novel therapy is especially relevant in a disease entity,
such as HFpEF that lacks a definitive standard of care. These data re-
inforce that the beneficial effects of sacubitril/valsartan on HF events
and cardiovascular mortality appear to extend up to an LVEF below
normal, including in ‘HF with mid-ranged ejection fraction’. Sacubitril/
valsartan is currently approved for use in HFrEF and is undergoing
regulatory review for use at higher LVEF. Defining single LVEF thresh-
olds for use is challenging given the inherent imprecision and variabil-
ity in LVEF assessment and since certain subgroups (such as women)
may derive benefits to a higher LVEF.16 Costs, access, and ease of im-
plementation will further modify the ultimate application of this ther-
apy in HF at higher ranges of LVEF.
However, certain limitations of applying a historical reference trial
should be acknowledged. Consistent with the differences in enrol-
ment periods between the active-controlled (2009–16) and historical
reference trials (1999–2001), there were marked differences in
comorbidity profiles and background therapies of enrolled subjects.
Since we only evaluate within-trial comparisons, balance in these
parameters (as a function of randomization) was maintained without
concern for confounding. Despite these substantial differences,
observed risk of total HF events and cardiovascular death between
CHARM-Preserved and PARAGON-HF was relatively comparable.
Furthermore, we evaluated relative treatment effects as these esti-
mates may be more similar across trials with varying designs, popula-
tions, and durations of follow-up compared with estimates of
absolute treatment effects. Left ventricular ejection fraction captured
was site-assessed (and not centrally measured); data quality may vary
across global sites. Certain trial design features may have contributed
to highly selected patient populations, including inclusion of only
ACEi-intolerant patients in CHARM-Alternative and of patients who
tolerated sequential run-in phases in PARADIGM-HF and
PARAGON-HF. These factors introduce uncertainty around the
exact estimate of treatment effect of sacubitril/valsartan vs. putative
placebo and limit the generalizability of our findings.
This putative placebo analysis across the full range of LVEF com-
plement and extend previous primary clinical trial findings, supporting
the robust clinical benefits of sacubitril/valsartan in HF, with most
pronounced effects observed at an ejection fraction up to 60%.
Supplementary material
Supplementary material is available at European Heart Journal online.
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